1887

Abstract

This study examined invasive recovered from invasive meningococcal disease (IMD) cases in Western Canada between 2009 and 2013. A total of 161 isolates from individual IMD cases were analysed for serogroup, serotype, serosubtype, PorA genotype, multi-locus sequence type and nucleotide sequence of their 4CMenB vaccine antigen genes. Sixty-nine isolates were serogroup B (MenB), 47 were serogroup Y (MenY), 22 were serogroup C (MenC), 19 were serogroup W (MenW), three were serogroup E and one was non-encapsulated. MenC, MenY and MenW were mainly clonal, represented primarily by clonal complex (cc) 11, cc23 or cc167, and cc22, respectively. In contrast, MenB were composed of eight different ccs together with 11 isolates not assigned to any known cc. Antigenic analysis and PorA genotyping confirmed the heterogeneity of MenB isolates, while such results supported the clonal nature of most MenC, MenY and MenW isolates. Thirty-four (21.1 %) isolates had at least one gene that encoded one matching vaccine protein component of the 4CMenB vaccine (i.e. PorA P1.4; fHbp variant 1.1; NHBA peptide 2; and NadA-1, -2, or -3). An additional 18 isolates had genes that encoded variant 1 or subfamily B factor H binding proteins of this same vaccine.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.079921-0
2014-11-01
2019-11-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/11/1490.html?itemId=/content/journal/jmm/10.1099/jmm.0.079921-0&mimeType=html&fmt=ahah

References

  1. Abdillahi H., Poolman J. T.. ( 1987;). Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. . FEMS Microbiol Lett 48:, 367–371. [CrossRef]
    [Google Scholar]
  2. Ashton F. E., Caugant D. A.. ( 2001;). The panmictic nature of Neisseria meningitidis serogroup B during a period of endemic disease in Canada. . Can J Microbiol 47:, 283–289. [CrossRef][PubMed]
    [Google Scholar]
  3. Ashton F. E., Ryan J. A., Borczyk A., Caugant D. A., Mancino L., Huang D.. ( 1991;). Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. . J Clin Microbiol 29:, 2489–2493.[PubMed]
    [Google Scholar]
  4. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., Comanducci M.. ( 2009;). Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. . Vaccine 27:, 2794–2803. [CrossRef][PubMed]
    [Google Scholar]
  5. Bennett D. E., Mulhall R. M., Cafferkey M. T.. ( 2004;). PCR-based assay for detection of Neisseria meningitidis capsular serogroups 29E, X, and Z. . J Clin Microbiol 42:, 1764–1765. [CrossRef][PubMed]
    [Google Scholar]
  6. Bettinger J. A., Scheifele D. W., Halperin S. A., Vaudry W., Findlow J., Borrow R., Medini D., Tsang R..members of the Canadian Immunization Monitoring Program, Active (IMPACT) ( 2013a;). Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). . Vaccine 32:, 124–130. [CrossRef][PubMed]
    [Google Scholar]
  7. Bettinger J. A., Deeks S. L., Halperin S. A., Tsang R., Scheifele D. W.. ( 2013b;). Controlling serogroup B invasive meningococcal disease: the Canadian perspective. . Expert Rev Vaccines 12:, 505–517. [CrossRef][PubMed]
    [Google Scholar]
  8. Bjune G., Høiby E. A., Grønnesby J. K., Arnesen O., Fredriksen J. H., Halstensen A., Holten E., Lindbak A. K., Nøkleby H.. & other authors ( 1991;). Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. . Lancet 338:, 1093–1096. [CrossRef][PubMed]
    [Google Scholar]
  9. Borrow R., Claus H., Guiver M., Smart L., Jones D. M., Kaczmarski E. B., Frosch M., Fox A. J.. ( 1997;). Non-culture diagnosis and serogroup determination of meningococcal B and C infection by a sialyltransferase (siaD) PCR ELISA. . Epidemiol Infect 118:, 111–117. [CrossRef][PubMed]
    [Google Scholar]
  10. Borrow R., Claus H., Chaudhry U., Guiver M., Kaczmarski E. B., Frosch M., Fox A. J.. ( 1998;). siaD PCR ELISA for confirmation and identification of serogroup Y and W135 meningococcal infections. . FEMS Microbiol Lett 159:, 209–214. [CrossRef][PubMed]
    [Google Scholar]
  11. Clarke S. C., Diggle M. A., Mölling P., Unemo M., Olcén P.. ( 2003;). Analysis of PorA variable region 3 in meningococci: implications for vaccine policy. ? Vaccine 21:, 2468–2473. [CrossRef][PubMed]
    [Google Scholar]
  12. Claus H., Maiden M. C. J., Maag R., Frosch M., Vogel U.. ( 2002;). Many carried meningococci lack the genes required for capsule synthesis and transport. . Microbiology 148:, 1813–1819.[PubMed]
    [Google Scholar]
  13. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Aricò B., Capecchi B., Giuliani M. M., Masignani V., Santini L.. & other authors ( 2002;). NadA, a novel vaccine candidate of Neisseria meningitidis.. J Exp Med 195:, 1445–1454. [CrossRef][PubMed]
    [Google Scholar]
  14. Dang V., Jamieson F. B., Wilson S., Rawte P., Crowcroft N. S., Johnson K., Tsang R. S. W., Deeks S. L.. ( 2012;). Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. . BMC Infect Dis 12:, 202. [CrossRef][PubMed]
    [Google Scholar]
  15. de Filippis I., Gopalan V., Huyen Y.. ( 2011;). PorA VR3 Typing Database: a web-based resource for the determination of PorA VR3 alleles of Neisseria meningitidis. . Infect Genet Evol 11:, 248–249. [CrossRef][PubMed]
    [Google Scholar]
  16. de Moraes J. C., Perkins B. A., Camargo M. C., Hidalgo N. T., Barbosa H. A., Sacchi C. T., Landgraf I. M., Gattas V. L., Vasconcelos H. G.. & other authors ( 1992;). Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. . Lancet 340:, 1074–1078. [CrossRef][PubMed]
    [Google Scholar]
  17. Finne J., Leinonen M., Mäkelä P. H.. ( 1983;). Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. . Lancet 322:, 355–357. [CrossRef][PubMed]
    [Google Scholar]
  18. Gilca R., Deceuninck G., Lefebvre B., Tsang R., Amini R., Gilca V., Douville-Fradet M., Markowski F., De Wals P.. ( 2012;). The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. . PLoS ONE 7:, e50659. [CrossRef][PubMed]
    [Google Scholar]
  19. Giuliani M. M., Adu-Bobie J., Comanducci M., Aricò B., Savino S., Santini L., Brunelli B., Bambini S., Biolchi A.. & other authors ( 2006;). A universal vaccine for serogroup B meningococcus. . Proc Natl Acad Sci U S A 103:, 10834–10839. [CrossRef][PubMed]
    [Google Scholar]
  20. Granoff D. M.. ( 2010;). Review of meningococcal group B vaccines. . Clin Infect Dis 50: (Suppl 2), S54–S65. [CrossRef][PubMed]
    [Google Scholar]
  21. Hoang L. M. N., Thomas E., Tyler S., Pollard A. J., Stephens G., Gustafson L., McNabb A., Pocock I., Tsang R., Tan R.. ( 2005;). Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. . Clin Infect Dis 40:, e38–e42. [CrossRef][PubMed]
    [Google Scholar]
  22. Jamieson F. B., Rawte P., Deeks S. L., Zhou J., Law D. K. S., Deng S., Tsang R. S. W.. ( 2013;). Genetic and antigenic characterization of invasive endemic serogroup B Neisseria meningitidis from Ontario, Canada, in 2001-2010. . J Med Microbiol 62:, 46–55. [CrossRef][PubMed]
    [Google Scholar]
  23. Johswich K. O., Zhou J., Law D. K. S., St Michael F., McCaw S. E., Jamieson F. B., Cox A. D., Tsang R. S. W., Gray-Owen S. D.. ( 2012;). Invasive potential of nonencapsulated disease isolates of Neisseria meningitidis. . Infect Immun 80:, 2346–2353. [CrossRef][PubMed]
    [Google Scholar]
  24. Law D. K. S., Lorange M., Ringuette L., Dion R., Giguère M., Henderson A. M., Stoltz J., Zollinger W. D., De Wals P., Tsang R. S. W.. ( 2006;). Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). . J Clin Microbiol 44:, 2743–2749. [CrossRef][PubMed]
    [Google Scholar]
  25. Lewis S., Sadarangani M., Hoe J. C., Pollard A. J.. ( 2009;). Challenges and progress in the development of a serogroup B meningococcal vaccine. . Expert Rev Vaccines 8:, 729–745. [CrossRef][PubMed]
    [Google Scholar]
  26. Lucidarme J., Comanducci M., Findlow J., Gray S. J., Kaczmarski E. B., Guiver M., Vallely P. J., Oster P., Pizza M.. & other authors ( 2010;). Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. . Clin Vaccine Immunol 17:, 919–929. [CrossRef][PubMed]
    [Google Scholar]
  27. Lucidarme J., Tan L., Exley R. M., Findlow J., Borrow R., Tang C. M.. ( 2011;). Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. . Clin Vaccine Immunol 18:, 1002–1014. [CrossRef][PubMed]
    [Google Scholar]
  28. Maiden M. C. J., Bygraves J. A., Feil E., Morelli G., Russell J. E., Urwin R., Zhang Q., Zhou J., Zurth K.. & other authors ( 1998;). Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. . Proc Natl Acad Sci U S A 95:, 3140–3145. [CrossRef][PubMed]
    [Google Scholar]
  29. Masignani V., Comanducci M., Giuliani M. M., Bambini S., Adu-Bobie J., Arico B., Brunelli B., Pieri A., Santini L.. & other authors ( 2003;). Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. . J Exp Med 197:, 789–799. [CrossRef][PubMed]
    [Google Scholar]
  30. Miller E., Salisbury D., Ramsay M.. ( 2001;). Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. . Vaccine 20: (Suppl 1), S58–S67. [CrossRef][PubMed]
    [Google Scholar]
  31. Murphy E., Andrew L., Lee K. L., Dilts D. A., Nunez L., Fink P. S., Ambrose K., Borrow R., Findlow J.. & other authors ( 2009;). Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.. J Infect Dis 200:, 379–389. [CrossRef][PubMed]
    [Google Scholar]
  32. Oster P., Lennon D., O’Hallahan J., Mulholland K., Reid S., Martin D.. ( 2005;). MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. . Vaccine 23:, 2191–2196. [CrossRef][PubMed]
    [Google Scholar]
  33. Richmond P. C., Marshall H. S., Nissen M. D., Jiang Q., Jansen K. U., Garcés-Sánchez M., Martinón-Torres F., Beeslaar J., Szenborn L.. & other authors ( 2012;). Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. . Lancet Infect Dis 12:, 597–607. [CrossRef][PubMed]
    [Google Scholar]
  34. Riou J. Y., Guibourdenche M.. ( 1992;). Laboratory Methods, Neisseria and Branhamella. Paris, France:: Institut Pasteur;.
    [Google Scholar]
  35. Sacchi C. T., Lemos A. P., Brandt M. E., Whitney A. M., Melles C. E. A., Solari C. A., Frasch C. E., Mayer L. W.. ( 1998;). Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. . Clin Diagn Lab Immunol 5:, 845–855.[PubMed]
    [Google Scholar]
  36. Santolaya M. E., O’Ryan M. L., Valenzuela M. T., Prado V., Vergara R., Muñoz A., Toneatto D., Graña G., Wang H.. & other authors ( 2012;). Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. . Lancet 379:, 617–624. [CrossRef][PubMed]
    [Google Scholar]
  37. Shao Z., Li W., Ren J., Liang X., Xu L., Diao B., Li M., Lu M., Ren H.. & other authors ( 2006;). Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. . Lancet 367:, 419–423. [CrossRef][PubMed]
    [Google Scholar]
  38. Sierra G. V. G., Campa H. C., Varcacel N. M., Garcia I. L., Izquierdo P. L., Sotolongo P. F., Casanueva G. V., Rico C. O., Rodriguez C. R., Terry M. H.. ( 1991;). Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. . NIPH Ann 14:, 195–207, discussion 208–210.[PubMed]
    [Google Scholar]
  39. Taha M. K.. ( 2000;). Simultaneous approach for nonculture PCR-based identification and serogroup prediction of Neisseria meningitidis. . J Clin Microbiol 38:, 855–857.[PubMed]
    [Google Scholar]
  40. Tsang R. S. W., Henderson A. M., Cameron M. L., Tyler S. D., Tyson S., Law D. K. S., Stoltz J., Zollinger W. D.. ( 2007;). Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. . J Clin Microbiol 45:, 1753–1758. [CrossRef][PubMed]
    [Google Scholar]
  41. Vedros N. A.. ( 1987;). Development of meningococcal serogroups. . In Evolution of Meningococcal Disease, pp. 33–37. Edited by Vedros N. A... Boca Raton, FL.:: CRC Press;.
    [Google Scholar]
  42. Wang X., Cohn A., Comanducci M., Andrew L., Zhao X., MacNeil J. R., Schmink S., Muzzi A., Bambini S.. & other authors ( 2011;). Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. . Vaccine 29:, 4739–4744. [CrossRef][PubMed]
    [Google Scholar]
  43. Warshawsky B., Desai S., Langley J.. ( 2009;). Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). . Can Commun Dis Rep 36:, 1–40.
    [Google Scholar]
  44. Xie O., Pollard A. J., Mueller J. E., Norheim G.. ( 2013;). Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. . Vaccine 31:, 2852–2861. [CrossRef][PubMed]
    [Google Scholar]
  45. Zhou J., Lefebvre B., Deng S., Gilca R., Deceuninck G., Law D. K. S., De Wals P., Tsang R. S. W.. ( 2012;). Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. . J Clin Microbiol 50:, 1545–1551. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.079921-0
Loading
/content/journal/jmm/10.1099/jmm.0.079921-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error